Last Updated on October 9, 2024 by The Health Master
Biocon Ltd said the US health regulator has issued Form 483 with 11 observations each for two sites in Bengaluru and six observations for a plant in Malaysia, following inspection of seven manufacturing facilities of its arm, Biocon Biologics.
As per US Food and Drug Administration (USFDA), Form 483 is issued to a firm’s management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
The USFDA conducted three on-site inspections of Biocon Biologics’ seven manufacturing facilities, spanning two sites in Bengaluru, India, and one in Johor, Malaysia, Biocon said in a regulatory filing.
The inspections started with the Bengaluru site on August 11, 2022, and concluded with the Malaysia site on August 30, 2022, it added.
At the conclusion of these inspections, the agency has issued Form 483s with 11 observations each for the two sites in Bengaluru and six observations for the Malaysia site,” the company said.
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications and computerized tools to aid risk assessment and investigations, and other procedural and facility upgrades, it added.
Biocon said the inspections were on account of three pre-approval inspections for biosimilar Bevacizumab, RH-Insulin, and Insulin Aspart and a capacity expansion inspection for biosimilar Trastuzumab.
“These included multiple drug substance and drug product facilities and other support infrastructure at these sites,” it added.
The company said it will submit Corrective and Preventive Action (CAPA), to the USFDA within the stipulated time frame.
“We do not expect the outcome of these inspections to impact the current supply of our products,” it added.
USFDA issues Form 483 with 2 observation to Alembic
USFDA issues Form 483 with one observation to Aurobindo Pharma subsidiary’s plant
USFDA issues Form 483 with 6 observations to Cipla
UFDA issues Form 483 to Cipla’s facility in MP
USFDA issues Form 483 with 6 observations to Sun Pharma
USFDA issues Form 483 for 4 observations to Zydus
QR code on APIs – Active Pharmaceutical Ingredients
USFDA issues Form 483 with 2 observation to Alembic
NPPA: Silver jubilee celebrations of NPPA
USFDA gives approval to Loperamide HCL and Simethicone Tablets
FDA sets timelines for various regulatory approvals: Maharashtra
USFDA gives final approval for Chlorthalidone Tablets USP
USFDA issues Form 483 with one observation to Aurobindo Pharma subsidiary’s plant
Pharma company fined for dumping medical waste in open
Penalty provision for Blood Banks / Centres not updating stock in time
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
